Document is current
Any future updates will be listed below
-
Authors
Apavaloaei, Anca https://orcid.org/0000-0001-6896-1199
Zhao, Qingchuan
Hesnard, Leslie https://orcid.org/0000-0002-4623-7703
Cahuzac, Maxime https://orcid.org/0000-0002-5395-8090
Durette, Chantal
Larouche, Jean-David
Hardy, Marie-Pierre
Vincent, Krystel
Brochu, Sylvie
Laverdure, Jean-Philippe https://orcid.org/0000-0002-9245-6413
Lanoix, Joël
Courcelles, Mathieu https://orcid.org/0000-0001-5961-8858
Gendron, Patrick
Lajoie, Mathieu https://orcid.org/0000-0001-9162-086X
Ruiz Cuevas, Maria Virginia https://orcid.org/0000-0002-9974-264X
Kina, Eralda
Perrault, Julie
Humeau, Juliette
Ehx, Grégory https://orcid.org/0000-0002-7018-1770
Lemieux, Sébastien https://orcid.org/0000-0001-5477-1386
Watson, Ian R. https://orcid.org/0000-0002-6025-3080
Speiser, Daniel E. https://orcid.org/0000-0003-2031-3250
Bassani-Sternberg, Michal https://orcid.org/0000-0002-1934-954X
Thibault, Pierre https://orcid.org/0000-0001-5993-0331
Perreault, Claude https://orcid.org/0000-0001-9453-7383
-
Funding
Funding for this research was provided by:
Canadian Cancer Society Research Institute (705604, 705604)
SynergiQC program (no grant reference number) Fonds Vaccins Thérapeutiques Contre le Cancer
SynergiQC program
- License Information
-
More Information
Article History
Received: 18 July 2023
Accepted: 14 April 2025
First Online: 22 May 2025
Competing interests
: A.A., K.V., M.-P.H., P.T. and C.P. are named inventors on patent applications filed by the Université de Montréal and covering TAs reported in this article (patent application number WO2024211992, titled Novel tumor antigens for melanoma and uses thereof; patent application number WO2024187278, titled Novel tumor antigens for lung cancer and uses thereof). P.T. and C.P. receive grant support and consultant fees from Epitopea. The other authors declare no competing interests.
